M&A

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Eisai to buy "dementia ecosystem" partner EcoNaviSta

Eisai's bid to develop an integrated care platform for dementia in Japan has moved forward with the acquisition of remote monitoring firm EcoNaviSta.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

Rumour confirmed as Mallinckrodt merges with Endo

Two pharmas that filed for bankruptcy protection due to opioid litigation in the US – Mallinckrodt and Endo – are rumoured to be in merger talks.

News

BMS absorbs CAR-T partner 2seventy bio for $286m

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.

News

Sun Pharma buys Checkpoint and its new cancer drug

Sun Pharma has agreed to acquire Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running short on cash.

AstraZeneca buys cell therapy biotech for up to $1bn

Eisai to buy "dementia ecosystem" partner EcoNaviSta

Taiho snaps up ADC partner Araris for up to $1.14bn

Rumour confirmed as Mallinckrodt merges with Endo

BMS absorbs CAR-T partner 2seventy bio for $286m

Sun Pharma buys Checkpoint and its new cancer drug

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

M&A

Editor's Picks